13 completed. 13 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 4 | Completed 4 |
Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Infigratinib - Advanced Malignant Solid Neoplasm, Cholangiocarcinoma | Phase 2 | Completed | Sameek Roychowdhury | 17 | 2020-01-16 | 2026-02-24 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Adavosertib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2019-01-16 | 2023-10-17 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) FGFR Inhibitor AZD4547 - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2016-05-31 | 2021-06-29 |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) Nivolumab - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2016-05-31 | 2021-04-06 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 122 | 2009-09-21 | 2020-06-09 |
Neuroblastoma (8) · Central Nervous System Neoplasms (6) · Lymphoma, Non-Hodgkin (6) · Osteosarcoma (6) · Rhabdomyosarcoma (6) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Medulloblastoma (4) · Rhabdoid Tumor (4) · Sarcoma (4) · Wilms Tumor (4) · Sarcoma, Ewing (3)
Neoplasms (12) · Neoplasms by Histologic Type (12) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Nerve Tissue (8) · Neoplasms, Neuroepithelial (8) · Neuroectodermal Tumors (8) · Lymphoma (7) · Neoplasms, Connective and Soft Tissue (7)
Nivolumab (2) · adavosertib (2) · AZD 6244 (1) · AZD4547 (1) · CTLA-4 Antigen (1) · Crizotinib (1) · Ipilimumab (1) · Irinotecan (1) · LY3023414 (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · Specimen Handling (1) · Vemurafenib (1) · X-Rays (1) · infigratinib (1)
National Cancer Institute (NCI) (10) · Children's Oncology Group (2) · Sameek Roychowdhury (1)
United States (13) · Puerto Rico (5) · Canada (3)
AeRang Kim (1) · Carl E Allen (1) · Crystal L Mackall (1) · Emily G Greengard (1) · Julia Glade-Bender (1) · Kristina A Cole (1) · Nilofer S Azad (1) · Sameek Roychowdhury, M.D. (1) · Siqing Fu (1) · Susan N Chi (1) · Theodore W Laetsch (1) · Yael P Mosse (1) · Young Kwang Chae (1)
PMID 31401903, PMID 23598171, PMID 28032129, PMID 31765263, PMID 32192573, PMID 32463741, PMID 33568345, PMID 35363510, PMID 36469840, PMID 38520670, PMID 38815151, PMID 38873934, PMID 41920422
U10CA180886 (5), UM1CA097452 (4), U10CA180820 (2), U24CA196172 (2), UM1CA186688 (1)